Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Bayer Aktiengesellschaft (BAYRY : OTC)

• Company Description    Bayer AG is a life science company with core competencies in the areas of health care and agriculture. With the company's focus completely on the Life Science businesses, a new organizational structure was introduced effective Jan 1, 2016. Bayer Group now comprise exclusively of the Life Science businesses. The company started reporting in three segments ' Pharmaceuticals, Consumer Health and Crop Science ' from the third quarter of 2019. Both Animal Health and Currenta were reported as discontinued operations in the quarter. The company acquired U.S. seed giant Monsanto in June, 2018. With the acquisition, Bayer now has the strongest portfolio of seed and crop protection products for a wide range of crops and indications, the best research and development platform and the leading digital farming business. Number of Employees: 92,815

• Price / Volume Information    Yesterday's Closing Price: $10.82 Daily Weekly Monthly 20 Day Moving Average: 403,894 shares Shares Outstanding: 3,929.70 (millions) Market Capitalization: $42,519.31 (millions) Beta: 0.66 52 Week High: $11.15 52 Week Low: $4.83 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 10.75% 10.94% 12 Week 33.74% 31.59% Year To Date 0.00% 0.00%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL Kaiser-Wilhelm-Allee 1 - Leverkusen,2M 51368 DEU ph: 49-21-4-30-1 fax: 49-21-4306-6328 peter.dahlhoff@bayer.com http://www.bayer.com

• General Corporate Information    Officers Werner Baumann - Chief executive officer and Chairman Wolfgang Nickl - Finance Hartmut Klusik - Human Resources; Technology Kemal Malik - Innovation Erica Mann - Management members Peer Information Bayer Aktiengesellschaft (AGN.) Bayer Aktiengesellschaft (NVS) Bayer Aktiengesellschaft (NVO) Bayer Aktiengesellschaft (LLY) Bayer Aktiengesellschaft (RHHBY) Bayer Aktiengesellschaft (JNJ) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: Large Cap Pharma Sector: Medical CUSIP: 072730302 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 09/01/25 Next Expected EPS Date: 03/04/26 Share - Related Items Shares Outstanding: 3,929.70 Most Recent Split Date: 9.00 (4.00:1) Beta: 0.66 Market Capitalization: $42,519.31 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.21% Current Fiscal Quarter EPS Consensus Estimate: $0.69 Indicated Annual Dividend: $0.02 Current Fiscal Year EPS Consensus Estimate: $1.42 Payout Ratio: 0.02 Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio: -0.15 Estmated Long-Term EPS Growth Rate: 1.42% Last Dividend Paid: NA - $0.00 Next EPS Report Date: 03/04/26

• Fundamental Ratios P/E Current FY Estimate: 7.59 Trailing 12 Months: 7.46 PEG Ratio: 5.35 Price Ratios Price/Book: 1.23 Price/Cash Flow: 2.86 Price / Sales: 0.84 EPS Growth vs. Year Ago Period: 142.86% vs. Previous Quarter: -51.43% Sales Growth vs. Year Ago Period: 3.07% vs. Previous Quarter: -7.33% ROE 12/31/25 - - 09/30/25 - 16.48 06/30/25 - 15.44 ROA 12/31/25 - - 09/30/25 - 4.82 06/30/25 - 4.49 Current Ratio 12/31/25 - - 09/30/25 - - 06/30/25 - 1.13 Quick Ratio 12/31/25 - - 09/30/25 - - 06/30/25 - 0.73 Operating Margin 12/31/25 - - 09/30/25 - 11.28 06/30/25 - 10.58 Net Margin 12/31/25 - - 09/30/25 - -0.68 06/30/25 - -7.61 Pre-Tax Margin 12/31/25 - - 09/30/25 - - 06/30/25 - -4.39 Book Value 12/31/25 - - 09/30/25 - - 06/30/25 - 8.81 Inventory Turnover 12/31/25 - - 09/30/25 - - 06/30/25 - 1.64 Debt-to-Equity 12/31/25 - - 09/30/25 - - 06/30/25 - 1.04 Debt-to-Capital 12/31/25 - - 09/30/25 - - 06/30/25 - 50.97

Powered by Zacks Investment Research ©